The deal priced below last closing price of $11.21. H.C. Wainwright is acting as sole book running manager for the offering.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE:
- Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally
- Gyre Therapeutics Achieves Key Milestone in Phase 3 Trial
- Gyre Therapeutics announces Hydronidone trial met primary endpoint
- Gyre Therapeutics announces common stock offering, no amount given
- Gyre Therapeutics Reports Q1 2025 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue